Moberg Pharma AB (publ) (STO:MOB)
Sweden
· Delayed Price · Currency is SEK 10.37
+0.12 (1.17%)
At close: Mar 6, 2026
Moberg Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 13.54 | 9.81 | - | 0.21 | - | Upgrade
|
| Revenue Growth (YoY) | 37.99% | - | - | - | - | Upgrade
|
| Cost of Revenue | 5.86 | 3.5 | - | - | - | Upgrade
|
| Gross Profit | 7.68 | 6.32 | - | 0.21 | - | Upgrade
|
| Selling, General & Admin | 32.14 | 28.97 | 24.86 | 21.07 | 18.51 | Upgrade
|
| Research & Development | 3.54 | 302.23 | 3.66 | 1.18 | 3.45 | Upgrade
|
| Other Operating Expenses | -0.68 | - | -0.61 | -1.52 | -2.23 | Upgrade
|
| Operating Expenses | 35 | 331.2 | 27.91 | 20.72 | 19.73 | Upgrade
|
| Operating Income | -27.32 | -324.89 | -27.91 | -20.52 | -19.73 | Upgrade
|
| Interest Expense | -0.18 | -0.23 | -0.26 | -0.07 | -0.13 | Upgrade
|
| Interest & Investment Income | 3.48 | 4.58 | 2.3 | 0.79 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.06 | 0.45 | 0.29 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | -24.02 | -320.47 | -25.42 | -19.51 | -19.97 | Upgrade
|
| Pretax Income | -24.02 | -320.47 | -25.42 | -19.51 | -19.97 | Upgrade
|
| Income Tax Expense | 3.22 | -65.36 | -4.33 | -3.8 | -3.75 | Upgrade
|
| Earnings From Continuing Operations | -27.24 | -255.11 | -21.09 | -15.71 | -16.22 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 23.59 | Upgrade
|
| Net Income to Company | -27.24 | -255.11 | -21.09 | -15.71 | 7.37 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.13 | Upgrade
|
| Net Income | -27.24 | -255.11 | -21.09 | -15.71 | 7.49 | Upgrade
|
| Net Income to Common | -27.24 | -255.11 | -21.09 | -15.71 | 7.49 | Upgrade
|
| Net Income Growth | - | - | - | - | 27.73% | Upgrade
|
| Shares Outstanding (Basic) | 47 | 38 | 16 | 8 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 38 | 16 | 8 | 4 | Upgrade
|
| Shares Change (YoY) | 23.78% | 138.46% | 109.19% | 76.28% | 127.45% | Upgrade
|
| EPS (Basic) | -0.58 | -6.74 | -1.33 | -2.07 | 1.74 | Upgrade
|
| EPS (Diluted) | -0.58 | -6.74 | -1.33 | -2.07 | 1.70 | Upgrade
|
| EPS Growth | - | - | - | - | -44.56% | Upgrade
|
| Free Cash Flow | -17.49 | -16.47 | -33.21 | -16.84 | -15.3 | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.43 | -2.09 | -2.22 | -3.55 | Upgrade
|
| Gross Margin | 56.73% | 64.37% | - | 100.00% | - | Upgrade
|
| Operating Margin | -201.77% | -3311.46% | - | -9911.59% | - | Upgrade
|
| Profit Margin | -201.18% | -2600.26% | - | -7589.37% | - | Upgrade
|
| Free Cash Flow Margin | -129.18% | -167.87% | - | -8136.23% | - | Upgrade
|
| EBITDA | -26.62 | -324.33 | -26.96 | -19.62 | -19.73 | Upgrade
|
| EBITDA Margin | -196.59% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.7 | 0.56 | 0.95 | 0.9 | 0 | Upgrade
|
| EBIT | -27.32 | -324.89 | -27.91 | -20.52 | -19.73 | Upgrade
|
| EBIT Margin | -201.77% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.